Rohlfing J J, Brunzell J D
West J Med. 1986 Aug;145(2):210-8.
Thiazide and loop diuretics increase triglyceride, total cholesterol and low-density-lipoprotein (LDL) cholesterol levels with no change in high-density-lipoprotein (HDL) cholesterol. beta-Adrenergic antagonists increase triglyceride and decrease HDL cholesterol levels. A rise in very-low-density-lipoprotein (VLDL) cholesterol balances the decrease in HDL cholesterol, so that there is no significant change in total cholesterol. alpha-Adrenergic antagonists decrease triglyceride, increase HDL cholesterol and may decrease VLDL and LDL cholesterol. Labetalol, with both alpha- and beta-adrenergic antagonistic activity, does not affect plasma lipids in a small number of studies. The calcium channel blockers nifedipine and verapamil also have no consistent effect on lipoprotein levels in a small number of studies.
噻嗪类利尿剂和袢利尿剂会使甘油三酯、总胆固醇和低密度脂蛋白(LDL)胆固醇水平升高,而高密度脂蛋白(HDL)胆固醇水平无变化。β-肾上腺素能拮抗剂会使甘油三酯升高,HDL胆固醇水平降低。极低密度脂蛋白(VLDL)胆固醇的升高平衡了HDL胆固醇的降低,因此总胆固醇无显著变化。α-肾上腺素能拮抗剂会降低甘油三酯,升高HDL胆固醇,还可能降低VLDL和LDL胆固醇。拉贝洛尔兼具α和β肾上腺素能拮抗活性,在少数研究中对血浆脂质无影响。少数研究中,钙通道阻滞剂硝苯地平和维拉帕米对脂蛋白水平也没有一致的影响。